Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Q2 Loss Rises Sharply on Acquisition Costs

NEW YORK (GenomeWeb News) – Clinical Data today posted a $70 million net loss for the second quarter, resulting primarily from charges related to its August acquisition of Adenosine Therapeutics.
 
The Newton, Mass.-based firm reported revenues of $8.8 million for the three-month period ended Sept. 30, down 3 percent from revenues of $9.1 million for the second quarter of 2007. Excluding $1.8 million in grant revenue recognized by Cogenics Icoria during last year’s second quarter, Clinical Data’s revenues increased 22 percent year over year. Late last year, Clinical Data wound down Icoria product lines that are no longer providing revenue for the firm.
 
The firm said that its PGxHealth division had 127 percent revenue growth year over year to $2.2 million, driven primarily by sales of its Familion cardiac tests. Exlcuding the Cogenics Icoria grant revenue from 2007, Cogenics’ genomic service business revenues grew 5 percent to $6.4 million.
 
Clinical Data’s net loss for the quarter was $70 million, or $3.30 per share, compared to a loss of $10.9 million, or $.57 per share, for the second quarter of 2007. The firm took a charge of $52.1 million during the quarter related to in-process research and development tied to its acquisition of Adenosine Therapeutics in August.
 
Clinical Data’s R&D spending increased more than three-fold to $9.4 million from $2.9 million, while its SG&A expenses rose around 17 percent to $10.9 million from $9.3 million.
 
The company held cash and cash equivalents of $41.2 million as of the end of its second quarter.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.